127 related articles for article (PubMed ID: 9337511)
1. Cost-effective analysis of mass screening for cervical cancer in Japan.
Matsunaga G; Tsuji I; Sato S; Fukao A; Hisamichi S; Yajima A
J Epidemiol; 1997 Sep; 7(3):135-41. PubMed ID: 9337511
[TBL] [Abstract][Full Text] [Related]
2. Determining the cost-effectiveness of mass screening for cervical cancer using common analytic models.
Sato S; Matunaga G; Tsuji I; Yajima A; Sasaki H
Acta Cytol; 1999; 43(6):1006-14. PubMed ID: 10578971
[TBL] [Abstract][Full Text] [Related]
3. [Cost-benefit analysis of the Program for Early Screening of Cervico-uterine Cancer].
Hernández-Peña P; Lazcano-Ponce EC; Alonso-de Ruiz P; Cruz-Valdez A; Meneses-González F; Hernández-Avila M
Salud Publica Mex; 1997; 39(4):379-87. PubMed ID: 9381251
[TBL] [Abstract][Full Text] [Related]
4. Debates about cervical screening: an historical overview.
Bryder L
J Epidemiol Community Health; 2008 Apr; 62(4):284-7. PubMed ID: 18339818
[No Abstract] [Full Text] [Related]
5. Cost-effectiveness of 3 methods to enhance the sensitivity of Papanicolaou testing.
Brown AD; Garber AM
JAMA; 1999 Jan; 281(4):347-53. PubMed ID: 9929088
[TBL] [Abstract][Full Text] [Related]
6. Cost-effective policies for cervical cancer screening. An international review.
Fahs MC; Plichta SB; Mandelblatt JS
Pharmacoeconomics; 1996 Mar; 9(3):211-30. PubMed ID: 10160098
[TBL] [Abstract][Full Text] [Related]
7. [Costs of population cervical cancer screening program in Poland between 2007-2009].
Spaczyński M; Karowicz-Bilinska A; Kedzia W; Molińska-Glura M; Seroczyński P; Januszek-Michalecka L; Rokita W; Nowak-Markwitz E
Ginekol Pol; 2010 Oct; 81(10):750-6. PubMed ID: 21117303
[TBL] [Abstract][Full Text] [Related]
8. Clinical and cost implications of new technologies for cervical cancer screening: the impact of test sensitivity.
Hutchinson ML; Berger BM; Farber FL
Am J Manag Care; 2000 Jul; 6(7):766-80. PubMed ID: 11067374
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of organized versus opportunistic cervical cytology screening in Hong Kong.
Kim JJ; Leung GM; Woo PP; Goldie SJ
J Public Health (Oxf); 2004 Jun; 26(2):130-7. PubMed ID: 15284314
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness analysis of different types of human papillomavirus vaccination combined with a cervical cancer screening program in mainland China.
Mo X; Gai Tobe R; Wang L; Liu X; Wu B; Luo H; Nagata C; Mori R; Nakayama T
BMC Infect Dis; 2017 Jul; 17(1):502. PubMed ID: 28720082
[TBL] [Abstract][Full Text] [Related]
11. De novo establishment and cost-effectiveness of Papanicolaou cytology screening services in the Socialist Republic of Vietnam.
Suba EJ; Nguyen CH; Nguyen BD; Raab SS;
Cancer; 2001 Mar; 91(5):928-39. PubMed ID: 11251944
[TBL] [Abstract][Full Text] [Related]
12. Interactive neural-network-assisted screening. An economic assessment.
Radensky PW; Mango LJ
Acta Cytol; 1998; 42(1):246-52. PubMed ID: 9479347
[TBL] [Abstract][Full Text] [Related]
13. Setting the target for a better cervical screening test: characteristics of a cost-effective test for cervical neoplasia screening.
Myers ER; McCrory DC; Subramanian S; McCall N; Nanda K; Datta S; Matchar DB
Obstet Gynecol; 2000 Nov; 96(5 Pt 1):645-52. PubMed ID: 11042294
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of cervical cancer screening: comparison of screening policies.
van den Akker-van Marle ME; van Ballegooijen M; van Oortmarssen GJ; Boer R; Habbema JD
J Natl Cancer Inst; 2002 Feb; 94(3):193-204. PubMed ID: 11830609
[TBL] [Abstract][Full Text] [Related]
15. [Effectiveness of cervical screening - expectation and reality].
Kostova P; Zlatkov V
Akush Ginekol (Sofiia); 2000; 39(3):23-4. PubMed ID: 11187989
[TBL] [Abstract][Full Text] [Related]
16. Cervical cancer screening program of Paraná: cost-effective model in a developing country.
Bleggi Torres LF; Werner B; Totsugui J; Collaço LM; Araújo SR; Huçulak M; Boza EJ; Fischer RM; De Laat L; Sobbania LC; Raggio A
Diagn Cytopathol; 2003 Jul; 29(1):49-54. PubMed ID: 12827718
[TBL] [Abstract][Full Text] [Related]
17. Duration of preclinical cervical cancer and reduction in incidence of invasive cancer following negative pap smears.
van Oortmarssen GJ; Habbema JD
Int J Epidemiol; 1995 Apr; 24(2):300-7. PubMed ID: 7635589
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of cervical-cancer screening in five developing countries.
Goldie SJ; Gaffikin L; Goldhaber-Fiebert JD; Gordillo-Tobar A; Levin C; Mahé C; Wright TC;
N Engl J Med; 2005 Nov; 353(20):2158-68. PubMed ID: 16291985
[TBL] [Abstract][Full Text] [Related]
19. The costs and effects of cervical and breast cancer screening in a public hospital emergency room. The Cancer Control Center of Harlem.
Mandelblatt J; Freeman H; Winczewski D; Cagney K; Williams S; Trowers R; Tang J; Gold K; Lin TH; Kerner J
Am J Public Health; 1997 Jul; 87(7):1182-9. PubMed ID: 9240110
[TBL] [Abstract][Full Text] [Related]
20. Effect of regular 3-yearly screening on the incidence of cervical smears: the Leiden experience.
Boon ME; de Graaff Guilloud JC; Rietveld WJ; Wijsman-Grootendorst A
Cytopathology; 1990; 1(4):201-10. PubMed ID: 2101670
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
